The Zantac Multi-District Litigation (MDL) consolidates thousands of lawsuits filed by individuals who claim they took Zantac made with ranitidine—which contained N-Nitrosodimethylamine (NDMA)—and developed cancer as a result. NDMA is a probable human carcinogen.
California Zantac JCCP
Judge Evelio Grillo, for the Superior Court of Alameda, California, has set October 10, 2022, as the trial date for the first U.S. Zantac trial. Judge Grillo oversees the California Ranitidine Product Cases Judicial Council Coordinated Proceedings (JCCP).
Zantac Florida Bellwether Trials in 2023
Judge Robin L. Rosenberg, who is overseeing the Zantac multidistrict litigation (MDL) in the U.S. District Court for the Southern District of Florida, scheduled the first bellwether trial for July 17, 2023.
On May 23, 2023, the Court will select the Plaintiffs for the first and second Phase One cancer category cases to be tried as the first and second bellwether trials, respectively.
Two days before this, on May 21, 2023, the parties will advise the court of their nominations and rankings for four cases each in the first and second Phase One cancer category cases.
The bellwether trials will affect more than 1,800 product liability cases that have been consolidated for pretrial discovery purposes.
However, the MDL’s initial pretrial discovery pool will comprise only those plaintiffs who reside in the state of Florida, partly because of the state’s middle-of-the-road laws, which would facilitate determining settlement values that could play out in cases from different districts across the country. Florida plaintiffs bear similarity to those in other states—in terms of demographics, ages, cancer types, products used, and duration of use—making them viable representatives for bellwether trials. Furthermore, the Florida court has the power to subpoena witnesses who have important, case-related information for the local plaintiffs.
Types of cancers that the parties will litigate in the MDL:
- Colorectal and intestinal cancer
- Bladder cancer
- Gastric cancer
- Esophageal cancer
- Lung cancer
- Prostate cancer
- Pancreatic cancer
Breast and kidney cancer cases will not be litigated as part of this MDL.
PREVIOUS FDA REACTION
In April 2020, the U.S. FDA requested that manufacturers withdraw their prescription and over-the-counter (OTC) ranitidine medications from the United States market. The FDA explained that the move was prompted by the detection of NDMA in ranitidine products—better known by the brand name Zantac.
PRETRIAL ORDER # 78 in MDL NO. 2924
DONE and ORDERED in Chambers, West Palm Beach, Florida, this 12th day of May, 2022.
The U.S. District Court Southern District of Florida, in a previous pretrial order, permitted individual Plaintiffs to unilaterally dismiss their cases without the need for a court order, to afford plaintiffs flexibility in deciding which cancers they pursue.
However, because this MDL is in the final stages of bellwether trial selection and Daubert challenges and the Court has begun the process of finalizing the claims and parties, the Court ordered the following.
As of July 1, 2022, the Court will deem any and all master answers in this MDL, together with any and all motions for summary judgment filed by Defendants, to be answers and motions that preclude an individual Plaintiff’s ability to unilaterally dismiss their case.
This is to close all pleadings in individual cases, so that the Court will know whether any individual claims against the retail Defendants remain in the MDL.